Juvenile arthritis damage index predicts poor response to biological treatment: A prospective cohort study

Figure 1 Baseline juvenile arthritis damage index item distribution in non-systemic juvenile idiopathic arthritis patients. JADI-A: Juvenile arthritis damage index - articular damage; JADI-E: Juvenile arthritis damage index - extraarticular damage; JIA: Juvenile idiopathic arthritis; oJIA: Oligoarthritis (persistent and extended); pJIA: Polyarthritis (rheumatoid factor positive and negative); PsJIA: Psoriatic arthritis; ERA: Enthesitis-related arthritis; GC: Glucocorticosteroids.

Figure 2 Dynamics of changes in juvenile arthritis damage index - articular damage and juvenile arthritis damage index - extraarticular damage indices compared to baseline after initiation of biological therapy. JADI-A: Juvenile arthritis damage index - articular damage; JADI-E: Juvenile arthritis damage index - extraarticular damage.

Figure 3 Dynamics of juvenile arthritis damage index during the study in juvenile idiopathic arthritis patients treated with different biological disease-modified antirheumatic drugs. JADI-A: Juvenile arthritis damage index-articular; BL: Baseline; EOS: End of study.

Figure 4 Distribution of damage in patients with different disease activities, according to the juvenile arthritis disease activity score 71 grade at the end of the study, P < 0. 001. JADI: Juvenile arthritis damage index; JADAS: Juvenile arthritis disease activity score.

Figure 5 The juvenile arthritis disease activity score 71 activity index dynamics during the study in Juvenile idiopathic arthritis patients with and without baseline damage. ^aP < 0.05. JADI: Juvenile arthritis damage index.